Literature DB >> 11960398

Sustained complete remission of chronic refractory immune thrombocytopenic purpura (ITP) of 10 years duration after only two infusions of rituximab.

Yossi Cohen, Aaron Polliack.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11960398     DOI： 10.1038/sj.thj.6200148

Source DB:  PubMed          Journal:  Hematol J        ISSN： 1466-4860


× No keyword cloud information.
  4 in total

Review 1.  Treatment of immune thrombocytopenic purpura in children : current concepts.

Authors:  Aziza T Shad; Corina E Gonzalez; S G Sandler
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

2.  Rituximab treatment for relapsed autoimmune hemolytic anemia in Evans syndrome.

Authors:  Anat Galor; Timothy O'Brien
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

3.  Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia.

Authors:  Vivek L Patel; Matthieu Mahévas; Soo Y Lee; Roberto Stasi; Susanna Cunningham-Rundles; Bertrand Godeau; Julie Kanter; Ellis Neufeld; Tillmann Taube; Ugo Ramenghi; Shalini Shenoy; Mary J Ward; Nino Mihatov; Vinay L Patel; Philippe Bierling; Martin Lesser; Nichola Cooper; James B Bussel
Journal:  Blood       Date:  2012-05-07       Impact factor: 22.113

4.  Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis.

Authors:  Jaime Garcia-Chavez; Abraham Majluf-Cruz; Laura Montiel-Cervantes; Miriam García-Ruiz Esparza; Jorge Vela-Ojeda
Journal:  Ann Hematol       Date:  2007-09-14       Impact factor: 3.673
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.